Apellis Pharmaceuticals, Inc. APLS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

48/100

1/7 Pass

SharesGrow Intrinsic Value

Apellis Pharmaceuticals, Inc. (APLS) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は Morningside Venture Investments Ltd 12,806,342 株保有. その他の主要保有者には Deschatelets Pascal および Francois Cedric.

過去12ヶ月間にインサイダーは 86 件の取引を実施 APLS 株式 — 32 件の買い (評価額 $19.26M) および 39 件の売り (評価額 $10.82M). インサイダーの売りが買いを上回っています.

APLS インサイダー保有状況

最大保有者

Morningside Venture Investments Ltd

12,806,342 株

買い（12ヶ月）

$19.26M 評価額

売り（12ヶ月）

$10.82M 評価額

12ヶ月取引活動

買い 37%

売り 45%

インサイダー上位保有者

#	氏名	役職	保有株数	最終申告日	相対規模
1	Morningside Venture Investments Ltd	10 Percent Owner	12,806,342	2021-11-18	100%
2	Deschatelets Pascal	Chief Scientific Officer	1,177,222	2026-01-30	9%
3	Francois Cedric	Chief Executive Officer	372,815	2026-03-13	3%
4	Sullivan Timothy Eugene	Chief Financial Officer	152,041	2026-01-30	1%
5	Watson David O.	General Counsel	144,517	2026-01-30	1%
6	Boucher Kelley	Chief People Officer	127,804	2026-01-30	1%
7	Nicholson Nur	Chief Technical Officer	116,338	2026-01-30	1%
8	Delong Mark Jeffrey	Chief Business & Strat Officer	114,591	2026-02-13	1%
9	Meltzer Leslie	Chief Research and Development	107,024	2026-01-30	1%
10	Grossi Federico	Chief Medical Officer	94,884	2023-01-09	1%
11	Baumal Caroline	Chief Medical Officer	86,527	2026-01-23	1%
12	Townsend Adam J.	Chief Commercial Officer	84,050	2025-01-30	1%
13	Lewis Karen	Chief People Officer	70,251	2025-01-30	1%
14	Chopas James George	VP/chief Accounting Officer	65,955	2026-01-30	1%
15	Eisele Jeffrey	Chief Development Officer	55,312	2025-01-30	0%
16	Scheibler Lukas	Chief Research Officer	39,391	2023-12-05	0%
17	Brown Victoria L.	Program Team Lead	23,556	2023-01-24	0%
18	Chan Gerald	Director	14,684	2026-01-05	0%
19	Dunlop A. Sinclair	Director	14,684	2026-01-05	0%
20	O'brien Stephanie Monaghan	Director	14,684	2026-01-05	0%

最近の取引 (過去12ヶ月)

日付	氏名	役職	種類	株数	株価	価値
2026-03-31	Biogen Inc.	Other: See Footnotes	不明	-	-	-
2026-03-11	Francois Cedric	Chief Executive Officer	贈与（受領）	64,869	-	-
2026-03-02	Dolsten Mikael	Director	不明	-	-	-
2026-02-27	Dolsten Mikael	Director	RSU 付与（制限付株式）	14,312	-	-
2026-02-11	Delong Mark Jeffrey	Chief Business & Strat Officer	情報に基づく売り	368	$22.15	$8.15K
2026-02-03	Francois Cedric	Chief Executive Officer	オプション行使（売却）	8,840	$3.76	$33.24K
2026-01-28	Meltzer Leslie	Chief Research and Development	RSU 付与（制限付株式）	45,220	-	-
2026-01-28	Boucher Kelley	Chief People Officer	RSU 付与（制限付株式）	30,146	-	-
2026-01-28	Delong Mark Jeffrey	Chief Business & Strat Officer	RSU 付与（制限付株式）	36,606	-	-
2026-01-28	Chopas James George	VP/chief Accounting Officer	RSU 付与（制限付株式）	16,150	-	-
2026-01-28	Nicholson Nur	Chief Technical Officer	RSU 付与（制限付株式）	45,220	-	-
2026-01-28	Sullivan Timothy Eugene	Chief Financial Officer	RSU 付与（制限付株式）	58,140	-	-
2026-01-28	Francois Cedric	Chief Executive Officer	RSU 付与（制限付株式）	195,952	-	-
2026-01-28	Deschatelets Pascal	Chief Scientific Officer	RSU 付与（制限付株式）	25,840	-	-
2026-01-28	Watson David O.	General Counsel	RSU 付与（制限付株式）	55,986	-	-
2026-01-22	Baumal Caroline	Chief Medical Officer	情報に基づく売り	2,797	$21.77	$60.88K
2026-01-22	Delong Mark Jeffrey	Chief Business & Strat Officer	情報に基づく売り	3,371	$21.77	$73.37K
2026-01-22	Chopas James George	VP/chief Accounting Officer	情報に基づく売り	2,064	$21.77	$44.92K
2026-01-22	Nicholson Nur	Chief Technical Officer	情報に基づく売り	7,725	$21.77	$168.14K
2026-01-22	Sullivan Timothy Eugene	Chief Financial Officer	情報に基づく売り	10,287	$21.77	$223.9K
2026-01-22	Francois Cedric	Chief Executive Officer	情報に基づく売り	27,192	$21.77	$591.84K
2026-01-22	Deschatelets Pascal	Chief Scientific Officer	情報に基づく売り	5,928	$21.77	$129.03K
2026-01-22	Watson David O.	General Counsel	情報に基づく売り	7,832	$21.77	$170.47K
2026-01-20	Baumal Caroline	Chief Medical Officer	情報に基づく売り	1,882	$19.79	$37.25K
2026-01-20	Delong Mark Jeffrey	Chief Business & Strat Officer	情報に基づく売り	1,334	$19.79	$26.4K